Turmeric for Patients With Basal Joint Arthritis

Not Applicable

Recruiting

• Conditions: Thumb Osteoarthritis
• Interventions: Dietary Supplement: Turmeric; Other: Placebo

• Registration Number: NCT03017118
• Lead Sponsor: Massachusetts General Hospital

Brief Summary

The aim of this study is to assess whether the use of a commercially available nutraceutical, turmeric, is an effective option to manage pain and stiffness in patients with basal joint arthritis. To conduct a pilot Randomized Controlled Trial evaluating the impact of turmeric on basal joint arthritis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-12-07
• Study First Submitted QC: 2017-01-09
• Study First Posted: 2017-01-11
• Study Start: 2017-08-09
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-11
• Last Update Posted: 2023-06-13
• Primary Completion: 2024-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• 40 years of age or older
• English fluency and literacy
• Seeking care for basal joint pain
• Tender over basal joint
• Positive distraction rotation test (rotation of the thumb metacarpal base while applying axial traction)
• Radiographic evidence of Eaton stage 1 and 2 only

Exclusion Criteria

• Secondary gains (litigations or worker compensation) procedures that may interfere with patients' motivation for treatment
• Inability or unwillingness to participate in a trial study
• Rheumatoid Arthritis or other inflammatory disorder diagnoses
• Post-traumatic osteoarthritis
• Patients on Coumadin/Steroids/NSAIDs/Tylenol
• Diabetes Mellitus
• Pregnant or lactating women
• Basal joint arthritis of Eaton stage 3
• Patients seeking other treatment for their basal joint arthritis (splint, corticosteroid injection, surgery)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Turmeric	Turmeric	Subjects in this group will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
Control	Placebo	Subjects in this group will receive a placebo pill 3 times per day for 6 weeks.

Primary Outcome Measures

Name	Time	Method
Change in baseline pain intensity	Enrollment, 6 weeks, and 3 months	0-10 ordinal rating of pain intensity
Change in baseline disability	Enrollment, 6 weeks, and 3 months	Disability measured by the QuickDASH

Trial Locations

Locations (1)

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States